Brokerages Set Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Target Price at $5.50

Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) have been assigned an average recommendation of “Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $5.50.

A number of equities analysts have recently issued reports on the stock. William Blair restated a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Monday, November 11th. Zacks Investment Research upgraded shares of Pieris Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $4.50 price target for the company in a research report on Thursday, November 28th. ValuEngine cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Pieris Pharmaceuticals in a research report on Monday, November 11th.

Shares of NASDAQ PIRS traded up $0.02 during trading hours on Friday, reaching $3.92. The stock had a trading volume of 15,628 shares, compared to its average volume of 720,274. The firm has a 50-day moving average of $3.60 and a 200-day moving average of $4.27. The firm has a market cap of $212.77 million, a price-to-earnings ratio of -7.81 and a beta of 1.32. Pieris Pharmaceuticals has a fifty-two week low of $2.39 and a fifty-two week high of $6.04.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings results on Monday, November 11th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.18. Pieris Pharmaceuticals had a negative return on equity of 132.02% and a negative net margin of 107.24%. The company had revenue of $15.13 million for the quarter, compared to analyst estimates of $6.28 million. Equities analysts anticipate that Pieris Pharmaceuticals will post -0.78 EPS for the current fiscal year.

In related news, major shareholder Bvf Partners L. P/Il sold 50,000 shares of Pieris Pharmaceuticals stock in a transaction on Friday, September 6th. The shares were sold at an average price of $4.50, for a total value of $225,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 6.59% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of PIRS. Alpine Group USVI LLC acquired a new position in Pieris Pharmaceuticals during the third quarter worth $147,000. Renaissance Technologies LLC grew its holdings in shares of Pieris Pharmaceuticals by 3.9% in the 2nd quarter. Renaissance Technologies LLC now owns 2,168,700 shares of the biotechnology company’s stock worth $10,193,000 after acquiring an additional 80,900 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Pieris Pharmaceuticals by 1,074.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,874 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 5,374 shares during the period. JPMorgan Chase & Co. increased its stake in Pieris Pharmaceuticals by 216.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 85,549 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 58,519 shares in the last quarter. Finally, Fosun International Ltd increased its stake in Pieris Pharmaceuticals by 63.8% in the 2nd quarter. Fosun International Ltd now owns 364,693 shares of the biotechnology company’s stock valued at $1,616,000 after purchasing an additional 142,000 shares in the last quarter. 51.27% of the stock is owned by institutional investors and hedge funds.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Read More: How is a management fee different from a performance fee?

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.